LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads) on and off LinkedIn. Learn more in our Cookie Policy.

Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings.

Verastem Oncology’s Post

View organization page for Verastem Oncology, graphic

Verastem Oncology

14,818 followers

3d

The FDA has accepted and granted Priority Review to our New Drug Application for our investigational combination of avutometinib, an oral RAF/MEK clamp, and defactinib, an oral FAK inhibitor, for the treatment of recurrent KRAS mutant Low-Grade Serous Ovarian Cancer (LGSOC). Learn more about this significant milestone for all of us at Verastem and the LGSOC community: https://lnkd.in/edExuHhv #LGSOC #NDA #OvarianCancer #VerastemOnc

4 Comments

VP Oncology Development Strategy

8h

Happy to see defactinib moving forward! 🤞🏼

Kourosh Parivar

Kourosh Parivar

President

3d

Congratulations to the Verastem team for a successful submission. Looking forward to a successful approval soon.

Project & Program Management | Stakeholder Engagement | Team Building | Problem Solver | Change Agent

3d

Outstanding work, Team Verastem!

Sr. Director of Global Regulatory Affairs

6h

Congrats Jon!

See more comments

To view or add a comment, sign in

Verastem Oncology

14,818 followers

View Profile Follow

Explore topics